| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/01.QAI.0000230318.40170.60 |
| P698 | PubMed publication ID | 16940858 |
| P50 | author | Marjorie Robert-Guroff | Q30651738 |
| David C. Montefiori | Q63302725 | ||
| P2093 | author name string | Susan W Barnett | |
| Bo Peng | |||
| David Venzon | |||
| Vaniambadi S Kalyanaraman | |||
| Indresh Srivastava | |||
| V Raúl Gómez-Román | |||
| Ruth H Florese | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| Adenoviridae | Q193447 | ||
| cytotoxicity | Q246181 | ||
| P304 | page(s) | 270-277 | |
| P577 | publication date | 2006-11-01 | |
| P1433 | published in | Journal of Acquired Immune Deficiency Syndromes | Q6294722 |
| P1476 | title | An adenovirus-based HIV subtype B prime/boost vaccine regimen elicits antibodies mediating broad antibody-dependent cellular cytotoxicity against non-subtype B HIV strains. | |
| P478 | volume | 43 |
| Q36363866 | A novel assay for antibody-dependent cell-mediated cytotoxicity against HIV-1- or SIV-infected cells reveals incomplete overlap with antibodies measured by neutralization and binding assays |
| Q35785031 | A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhe |
| Q91638927 | ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type |
| Q36625165 | Adenoviral vectors elicit humoral immunity against variable loop 2 of clade C HIV-1 gp120 via "Antigen Capsid-Incorporation" strategy |
| Q59352288 | Antibody-dependent cellular cytotoxicity in HIV infection |
| Q27320687 | Antigenic properties of the human immunodeficiency virus envelope glycoprotein gp120 on virions bound to target cells |
| Q61641053 | Characterization of immune responses elicited in mice by intranasal co-immunization with HIV-1 Tat, gp140 ΔV2Env and/or SIV Gag proteins and the nontoxicogenic heat-labile Escherichia coli enterotoxin |
| Q37742680 | Chlamydial Type III Secretion System Needle Protein Induces Protective Immunity against Chlamydia muridarum Intravaginal Infection. |
| Q34600955 | Combining viral vectored and protein-in-adjuvant vaccines against the blood-stage malaria antigen AMA1: report on a phase 1a clinical trial |
| Q36961218 | Comparative study of Tat vaccine regimens in Mauritian cynomolgus and Indian rhesus macaques: influence of Mauritian MHC haplotypes on susceptibility/resistance to SHIV(89.6P) infection |
| Q37460091 | Comparison of antibodies that mediate HIV type 1 gp120 antibody-dependent cell-mediated cytotoxicity in asymptomatic HIV type 1-positive men and women. |
| Q64375028 | Comparison of systemic and mucosal immunization with replicating Single cycle Adenoviruses |
| Q37347813 | Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines. |
| Q91210566 | Deletion of multiple genes induces virulence reduction of vaccinia virus Tiantan strain |
| Q36479067 | Development of IgG Mediated Antibody Dependent Cell-mediated Cytotoxicity (ADCC) in the Serum and Genital Mucosa of HIV Seroconverters |
| Q64374898 | Divergent HIV-1-Directed Immune Responses Generated by Systemic and Mucosal Immunization with Replicating Single-Cycle Adenoviruses in Rhesus Macaques |
| Q35069126 | Early short-term antiretroviral therapy is associated with a reduced prevalence of CD8(+)FoxP3(+) T cells in simian immunodeficiency virus-infected controller rhesus macaques |
| Q37646897 | Enhanced FCGR2A and FCGR3A signaling by HIV viremic controller IgG. |
| Q42257677 | Fc receptor-mediated immune responses: new tools but increased complexity in HIV prevention |
| Q89552900 | Genetic Adjuvants in Replicating Single-Cycle Adenovirus Vectors Amplify Systemic and Mucosal Immune Responses against HIV-1 Envelope |
| Q34016756 | IIIa deleted adenovirus as a single-cycle genome replicating vector |
| Q64084496 | Induction of Fc-Mediated Effector Functions Against a Stabilized Inner Domain of HIV-1 gp120 Designed to Selectively Harbor the A32 Epitope Region |
| Q89978176 | Influenza A Virus Antibodies with Antibody-Dependent Cellular Cytotoxicity Function |
| Q64263004 | Knowns and Unknowns of Assaying Antibody-Dependent Cell-Mediated Cytotoxicity Against HIV-1 |
| Q33966586 | Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques |
| Q37677278 | Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles |
| Q35208657 | Neutralizing and other antiviral antibodies in HIV-1 infection and vaccination |
| Q36758574 | Problems and emerging approaches in HIV/AIDS vaccine development |
| Q38096489 | Recent advances in antibody-inducing poxviral and adenoviral vectored vaccine delivery platforms for difficult disease targets |
| Q64376800 | Replicating adenovirus HIV/SIV recombinant priming alone or in combination with a gp140 protein boost results in significant control of viremia following a SHIV89.6P challenge in Mamu-A*01 negative rhesus macaques |
| Q56993265 | Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development |
| Q35940685 | Replicating adenovirus-simian immunodeficiency virus (SIV) vectors efficiently prime SIV-specific systemic and mucosal immune responses by targeting myeloid dendritic cells and persisting in rectal macrophages, regardless of immunization route |
| Q36464587 | Replicating and non-replicating viral vectors for vaccine development |
| Q37803320 | Role of adjuvants in modeling the immune response |
| Q36097089 | Seroprevalence of neutralizing antibodies to adenovirus type 5 among children in India: implications for recombinant adenovirus-based vaccines |
| Q47282517 | Single-cycle adenovirus vectors in the current vaccine landscape |
| Q30238730 | Survivors Remorse: antibody-mediated protection against HIV-1. |
| Q37297052 | Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge |
| Q24652185 | The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? |
| Q41519074 | Therapeutic envelope vaccination in combination with antiretroviral therapy temporarily rescues SIV-specific CD4⁺ T-cell-dependent natural killer cell effector responses in chronically infected rhesus macaques |
| Q28730561 | Use of a polyanionic carbomer, Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoprotein |
| Q34810713 | Vaccine-elicited SIV and HIV envelope-specific IgA and IgG memory B cells in rhesus macaque peripheral blood correlate with functional antibody responses and reduced viremia |
| Q90226623 | Viral Vectors for the Induction of Broadly Neutralizing Antibodies against HIV |
Search more.